We observed in our previous study [10] that NSC 119889, a cell-permeable, competitive inhibitor of AdoMet (SAM), inhibited global cap-dependent translation initiation of 5'-m7G-capped mRNAs in general, but it increased cap-independent translation initiation of p27 mRNA through its 5'-UTR in estrogen receptor (ER) -negative MDA-MB-231 human breast cancer cells in vitro. Here, CDKN1B is linked to breast carcinoma.